Story
Zoetis Stock Rebounds Despite Drastic Cut to 2026 Financial Guidance

Zoetis Inc. (ZTS) shares rebounded from an early session low to trade higher on Tuesday, even after the animal health giant drastically cut its full-year financial forecast, citing significant pressure on its U.S. companion animal business. The volatile session followed a second-quarter report that narrowly beat profit expectations but missed on revenue.
Guidance Slashed on U.S. Weakness
Zoetis significantly lowered its outlook for the full 2026 fiscal year, signaling persistent challenges in its core market. The company issued the following updated guidance:
- Adjusted EPS: $6.15 to $6.25, falling far short of the analyst consensus of $6.87.
- Annual Revenue: $9.12 to $9.32 billion, a sharp reduction from its prior range of $9.68 to $9.96 billion.
CEO Kristin Peck attributed the downgrade to headwinds in its largest segment, companion animals, where U.S. revenue fell 7% during the quarter. In the company's report, Peck pointed to fewer visits to veterinary clinics, increased price sensitivity among pet owners, and intensifying competition as key factors. A partial offset came from the international business, where revenue grew by 6%.
Mixed Q2 Results and Leadership Change
AdThe guidance cut overshadowed a mixed second-quarter performance. Zoetis reported an adjusted earnings per share of $1.87, just one cent ahead of the $1.86 analyst consensus. However, quarterly revenue of approximately $2.5 billion was flat year-over-year and fell short of market expectations.
In a separate announcement, the company appointed Jay Saccaro as its new Executive Vice President, CFO, and COO. Saccaro, who was previously the CFO of GE HealthCare, will assume the newly combined role on August 17, uniting finance and manufacturing operations.
Market Reaction and Context
The stock's reaction was turbulent. After an initial sell-off that pushed shares to a session low of $73.72, the price recovered into positive territory. This resilience may reflect investor sentiment that much of the negative news was already priced in, as the stock has lost roughly half its value over the past 12 months and recently hit a 52-week low.
The challenges at Zoetis stand in contrast to peer IDEXX Laboratories, which recently raised its own annual profit forecast, suggesting a performance divergence within the animal health sector. Investors appear to be weighing the company's compressed valuation against the clear structural headwinds in its core U.S. market.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.